Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
107.2M
Cash
10.79M
Avg Qtr Burn
N/A
Short % of Float
0.14%
Insider Ownership
1.15%
Institutional Own.
50.11%
Qtr Updated
11/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Trogarzo® 90-Second Intravenous (IV) Details Human immunodeficiency virus | Approved Quarterly sales | |
EGRIFTA SV® (tesamorelin for injection) Details Human immunodeficiency virus, Abdominal Fat | PDUFA Approval decision | |
Tesamorelin (F8 Formulation) Details Human immunodeficiency virus, Abdominal Fat | PDUFA Approval decision | |
Trogarzo® Intramuscular (IM) Details Human immunodeficiency virus | BLA Resubmission | |
Sudocetaxel Zendusortide (TH1902) Details Cancer, Ovarian cancer | Phase 1b Update |